Wound care giant Acelity buys U.K.’s Crawford Healthcare for undisclosed price

Texas-based wound care giant Acelity has acquired the U.K.'s Crawford Healthcare for an undisclosed price. (Pixabay/Geralt)

Acelity, a U.S.-based giant in the wound care industry, has acquired Crawford Healthcare of the U.K. for an undisclosed price.

Crawford, which specializes in treatments for the care and repair of skin, offers wound care dressings such as the popular KerraMax Care and KerraFoam and KerraCel in the foam and antimicrobial gelling fiber categories, the company said.

Financial terms of the deal weren’t disclosed, though Acelity will get all of Crawford’s commercial products, R&D capabilities and manufacturing operations located in Cheshire, Engand.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Acelity, which is based in San Antonio, Texas, is known for its collagen dressing Promogran Prisma Matrix, as well as the Tielle Dressing Family and Adaptic Dressings.

“This transaction solidifies our ability to offer the most comprehensive line of wound care solutions and will enable us to create and consolidate leading positions in high-growth market segments, expand and strengthen our customer relationships, and enhance our innovation expertise for the benefit of clinicians and patients around the world,” R. Andrew Eckert, Acelity’s president and CEO, said in a statement.

The combination of each company’s respective wound dressing products with Acelity’s negative pressure wound therapy platforms is intended to create a broad portfolio for global wound care, the company said.


Suggested Articles

The FDA warned healthcare providers about cybersecurity vulnerabilities within certain clinical information systems made by GE Healthcare.

Weeks after receiving FDA approval for its in-office eardrum tube device, Tusker Medical has been picked up by Smith & Nephew for an undisclosed sum.

As public fascination with at-home DNA tests begins to wane, 23andMe announced that it will lay off about 100 of its staff, according to CNBC.